4Q Revenues: $701 million (-17%)
4Q Earnings: $66.6 million (-57%)
FY Revenues: $2.6 billion (+21%)
FY Earnings: $144.4 million (earnings were $657 million FY14)
Comments: Soliris sales were $689 million in the quarter, up 15%. For the year, Soliris sales were $2.6 billion, up 21%. Strensiq sales were $11.6 million in the quarter and $12 million for the year. Strensiq was approved by the FDA for the treatment of perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP) in 4Q15. R&D expenses were $191 million, up 48%.